Dapagliflozin for the treatment of type 2 diabetes mellitus–an update
MK Nicholson, R Ghazal Asswad… - Expert opinion on …, 2021 - Taylor & Francis
MK Nicholson, R Ghazal Asswad, JPH Wilding
Expert opinion on pharmacotherapy, 2021•Taylor & FrancisIntroduction Diabetes is a global health concern with a prevalence of 463 million people.
Importantly, despite the availability of numerous antidiabetic medications, type 2 diabetes
mellitus (T2DM) is still associated with significant morbidity and mortality worldwide. One
particular drug of interest is dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2)
inhibitor that is commonly used in the treatment of Type 2 Diabetes Mellitus (T2DM). Areas
covered This review outlines the current use and pharmacology of dapagliflozin, with a …
Importantly, despite the availability of numerous antidiabetic medications, type 2 diabetes
mellitus (T2DM) is still associated with significant morbidity and mortality worldwide. One
particular drug of interest is dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2)
inhibitor that is commonly used in the treatment of Type 2 Diabetes Mellitus (T2DM). Areas
covered This review outlines the current use and pharmacology of dapagliflozin, with a …
Introduction
Diabetes is a global health concern with a prevalence of 463 million people. Importantly, despite the availability of numerous antidiabetic medications, type 2 diabetes mellitus (T2DM) is still associated with significant morbidity and mortality worldwide. One particular drug of interest is dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is commonly used in the treatment of Type 2 Diabetes Mellitus (T2DM).
Areas covered
This review outlines the current use and pharmacology of dapagliflozin, with a specific focus on recent evidence regarding benefits in patients with cardiovascular and chronic kidney disease. The article includes an overview of the efficacy and safety of this drug and provides the reader with the expert opinion and perspectives of the authors.
Expert opinion
Increasing evidence of the beneficial effects on morbidity and mortality in patients with Type 2 diabetes and concurrent heart failure, acute MI and renal failure are likely to see the usage of dapagliflozin in patients with these comorbidities increase over the next 5 years.
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果